Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections.
BACKGROUND: Schistosomiasis has a considerable impact on public health in many tropical and subtropical areas. In the new world, schistosomiasis is caused by the digenetic trematode Schistosoma mansoni. Chemotherapy is the main measure for controlling schistosomiasis, and the current drug of choice...
Main Authors: | Regina Coeli, Elio H Baba, Neusa Araujo, Paulo M Z Coelho, Guilherme Oliveira |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3868512?pdf=render |
Similar Items
-
Association of oxamniquine praziquantel and clonazepam in experimental Schistosomiasis mansoni
by: Neusa Araujo, et al.
Published: (2008-12-01) -
Activity of praziquantel on in vitro transformed Schistosoma mansoni sporocysts
by: ACA Mattos, et al.
Published: (2006-10-01) -
Oxamniquine, praziquantel and lovastatin association in the experimental Schistosomiasis mansoni
by: Neusa Araújo, et al.
Published: (2008-08-01) -
Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails
by: Flávia FB Couto, et al.
Published: (2011-03-01) -
Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
by: Eglal I. Amer, et al.
Published: (2022-03-01)